Evidence map›Paper›PMID 42675550›Full record

Trial reportDiabetes, obesity & metabolism2026

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.

Eslam Montaser, Kanchan Bhasin, Davida Kruger, Halis Kaan Akturk, Andrew Ahmann, Janet K Snell-Bergeon, Viral N Shah

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eslam MontaserDivision of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-3138-1964
Kanchan BhasinDivision of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-2487-0142
Davida KrugerDivision of Endocrinology Diabetes and Metabolism, Henry Ford Hospital, Detroit, Michigan, USA.
Halis Kaan AkturkBarbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0003-4518-5179
Andrew AhmannOHSU Harold Schnitzer Diabetes Health Center, Portland, Oregon, USA.ORCID https://orcid.org/0000-0002-4544-5404
Janet K Snell-BergeonBarbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0002-9337-3740
Viral N ShahDivision of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-3827-7107

Funding

Breakthrough T1DNovo Nordisk
6 · The paper itself

Abstract

aimsTo evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST-T1D randomised controlled trial. MATERIALS AND

methodsContinuous glucose monitoring (CGM) data were collected during a 12-week extension phase after the ADJUST-T1D trial. Analyses included participants previously randomised to semaglutide who discontinued treatment (n = 16) and participants previously randomised to placebo who did not receive a glucagon-like peptide-1 receptor agonist during follow-up (n = 22). Changes in CGM-derived metrics from Week 26 to the extension phase were compared using Wilcoxon rank-sum tests with Benjamini-Hochberg adjustment. Analysis of covariance (ANCOVA) adjusting for Week 26 values was performed as a sensitivity analysis.

resultsCompared with placebo, participants who discontinued semaglutide experienced a greater decline in time in range (70-180 mg/dL) (median change -3.6% vs. 1.5%; adjusted p = 0.044). Semaglutide discontinuation was also associated with greater increases in glucose standard deviation (6.0 vs. 1.2 mg/dL; adjusted p = 0.044) and coefficient of variation (3.1% vs. 1.1%; adjusted p = 0.044), indicating worsening glycaemic variability. Time above range (> 180 mg/dL) increased numerically but did not remain significant after adjustment (adjusted p = 0.064). No significant between-group differences were observed in hypoglycaemia-related CGM metrics. ANCOVA analyses showed consistent findings.

conclusionsIn adults with Type 1 diabetes and obesity, semaglutide discontinuation was associated with a greater decline in time in range and increased glycaemic variability compared with placebo over 12 weeks. These findings suggest that glycaemic benefits achieved during treatment may not be fully sustained following withdrawal.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulinSemaglutideAdultContinuous Glucose MonitoringFemaleGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinGlycemic ControlHumansHypoglycemiaInsulin Infusion SystemsMaleMiddle AgedBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsInsulinSemaglutideautomated insulin deliverycontinuous glucose monitoringGLP‐1 receptor agonistglycaemic variabilityType 1 diabetes

Identifiers

PMID42675550
PMCPMC13646344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.